INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 49m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
SEC FORM 4/Option exerciseVerified data

Paolini John F. reported KNSA

CHIEF MEDICAL OFFICER · Kiniksa Pharmaceuticals International, plc · Kiniksa Pharmaceuticals International, plc — Restricted Share Unit

Side
M
Value
—
Shares
2,497
Price
—
Executed
Apr 7, 2026
Disclosed
Apr 8, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Apr 7 executedApr 8, 2026 disclosed

KNSA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · KNSA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$143K
    6,263 sh
    		Nov 2, 2026Nov 3, 2026
    traded Nov 2, 2026
    		+1dSEC FORM 4

    Evidence

    0
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M—
    16.1K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    7
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M—
    10.9K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    4
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M—
    9,412 sh
    		Nov 2, 2026Nov 3, 2026
    traded Nov 2, 2026
    		+1dSEC FORM 4

    Evidence

    4
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M—
    12.3K sh
    		Nov 2, 2026Nov 3, 2026
    traded Nov 2, 2026
    		+1dSEC FORM 4

    Evidence

    0
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M—
    6,263 sh
    		Nov 2, 2026Nov 3, 2026
    traded Nov 2, 2026
    		+1dSEC FORM 4

    Evidence

    10
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$268K
    12.3K sh
    		Nov 2, 2026Nov 3, 2026
    traded Nov 2, 2026
    		+1dSEC FORM 4

    Evidence

    10
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$173K
    16.1K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    10
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$234K
    21.1K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$45K
    3,760 sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    0
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$22K
    1,658 sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$286K
    16.1K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    2
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Option exercise · 10b5-1 plan
    		M$197K
    10.9K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    18
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Open-market sale · 10b5-1 plan
    		SELL$3.48M
    37.8K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    18
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Open-market sale · 10b5-1 plan
    		SELL$1.40M
    15.1K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    15
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Open-market sale · 10b5-1 plan
    		SELL$792K
    8,430 sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    15
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Open-market sale · 10b5-1 plan
    		SELL$596K
    6,282 sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    15
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Open-market sale · 10b5-1 plan
    		SELL$353K
    3,672 sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    8
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Open-market sale · 10b5-1 plan
    		SELL$171K
    1,760 sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    15
    MR
    Moat RossCHIEF OPERATING OFFICER
    KNSAKiniksa Pharmaceuticals International, plc
    Open-market sale · 10b5-1 plan
    		SELL$252K
    2,575 sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001741533-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 7, 2026
    Published
    Apr 8, 2026
    Ingested by INSIDER
    Nov 5, 04:06 UTC
    Last re-read
    Nov 5, 04:07 UTC

    Extracted facts

    Filer
    Paolini John F.
    Role
    CHIEF MEDICAL OFFICER
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Kiniksa Pharmaceuticals International, plc — Restricted Share Unit
    Ticker
    KNSA
    Shares
    2,497
    Price per share
    $0
    Execution date (reported)
    Apr 7, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    1

    What this establishes

    Paolini John F. filed this Form 4 reporting a option exercise of KNSA on Apr 7, 2026. It became public on Apr 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    CHIEF MEDICAL OFFICER
    Paolini John F.cik:0001741533
    Issuer
    Kiniksa Pharmaceuticals International, plccik:0001730430

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.